These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 23538970

  • 1. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
    Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT.
    J Nerv Ment Dis; 2013 Apr; 201(4):266-73. PubMed ID: 23538970
    [Abstract] [Full Text] [Related]

  • 2. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, Li T, Pedersen R, Keller M.
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [Abstract] [Full Text] [Related]

  • 3. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA.
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [Abstract] [Full Text] [Related]

  • 4. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
    Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT.
    Biol Psychiatry; 2007 Dec 15; 62(12):1371-9. PubMed ID: 17825800
    [Abstract] [Full Text] [Related]

  • 5. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA.
    Depress Anxiety; 2011 Feb 15; 28(2):137-44. PubMed ID: 21284066
    [Abstract] [Full Text] [Related]

  • 6. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
    Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R.
    Am J Psychiatry; 2010 Mar 15; 167(3):281-8. PubMed ID: 20008946
    [Abstract] [Full Text] [Related]

  • 7. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.
    Depress Anxiety; 2002 Mar 15; 16(1):4-13. PubMed ID: 12203668
    [Abstract] [Full Text] [Related]

  • 8. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M.
    Ann Clin Psychiatry; 2007 Mar 15; 19(1):5-8. PubMed ID: 17453655
    [Abstract] [Full Text] [Related]

  • 9. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M, Kopecek M, Novak T, Stopkova P, Sos P, Kozeny J, Brunovsky M, Höschl C.
    J Affect Disord; 2009 Nov 15; 118(1-3):94-100. PubMed ID: 19249105
    [Abstract] [Full Text] [Related]

  • 10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 15; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB, Thase ME, EPIC 014 Study Group.
    J Psychiatr Res; 2007 Dec 15; 41(3-4):351-9. PubMed ID: 16165158
    [Abstract] [Full Text] [Related]

  • 12. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Gao K, Cui X, Nierenberg AA, OPERATION Study Team.
    J Clin Psychopharmacol; 2010 Aug 15; 30(4):357-64. PubMed ID: 20571433
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
    Plesnicar BK.
    Psychiatr Danub; 2010 Sep 15; 22(3):413-7. PubMed ID: 20856184
    [Abstract] [Full Text] [Related]

  • 14. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
    Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, Campbell GM, Corya SA.
    J Clin Psychiatry; 2009 Mar 15; 70(3):387-96. PubMed ID: 19284928
    [Abstract] [Full Text] [Related]

  • 15. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.
    J Psychopharmacol; 2002 Sep 15; 16(3):215-9. PubMed ID: 12236627
    [Abstract] [Full Text] [Related]

  • 16. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT.
    J Clin Psychiatry; 2007 Aug 15; 68(8):1246-56. PubMed ID: 17854250
    [Abstract] [Full Text] [Related]

  • 17. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS, Aguiar LM, Kunz NR, Lei D.
    J Psychiatr Res; 2004 Aug 15; 38(3):249-57. PubMed ID: 15003430
    [Abstract] [Full Text] [Related]

  • 18. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul 15; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 19. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 20. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan 30; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.